Overview

High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

Status:
Completed
Trial end date:
2019-09-26
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of high-intensity rosuvastatin and moderate-intensity rosuvastatin/ezetimibe in ASCVD patients.
Phase:
Phase 4
Details
Lead Sponsor:
Yuhan Corporation
Treatments:
Ezetimibe
Rosuvastatin Calcium